How Far Can BSX Stock Swing After Losing More Than Half Its Value?

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

How Much Could You Lose At The $28 Floor?

Options expiring in about 362 days carry an implied volatility of 43.1%, which puts roughly a two-in-three chance on the stock ending inside that band.

For a holder, the floor means losing $15.26 a share, about 35% of today’s price. The ceiling means gaining $23.44, or about 54%. The floor is not the limit either: the market leaves about a 16% chance, roughly one in six, that the stock finishes below $28.46.

The ceiling sits further away because a stock cannot fall below zero but can rise without limit. Even that ceiling is far below the $104.98 high of the past 52 weeks. Anyone who bought near the top would still be under water at the upper end of the band.

Is The Market Pricing More Movement Than BSX Has Shown?

Only slightly. Implied volatility runs at 1.12 times the stock’s realized volatility of 38.4% over the trailing year. That small markup is the usual premium option sellers charge for taking on risk.

The catch is what the 38.4% measured: a year in which the shares fell by more than half. The market is pricing about the same turbulence again.

Management’s revised outlook highlights ongoing operational volatility across its core franchises. In July, Boston Scientific cut its 2026 guidance for the second time, and management said the reduction was concentrated in two areas. The U.S. market for WATCHMAN, its heart device for stroke prevention, slowed sharply as mounting clinical evidence changed referral patterns. In electrophysiology—the business built on its FARAPULSE technology—competitors took more U.S. share than management expected.

What Would Push BSX Toward Either End?

The case for the lower end begins with near-term disruption: a cyberattack in late August disrupted manufacturing and order shipments, which the company says is likely to have a material impact on third-quarter and full-year 2026 results. Beyond that, the pressure continues into WATCHMAN. Management is not assuming any improvement in WATCHMAN growth in 2027, and it expects a new competitor to take some share that year.

The case for the upper end rests on the rest of the company. The business units outside WATCHMAN and electrophysiology make up roughly 75% of revenue, and management expects them to grow about 6% in the second half of 2026. It also expects growth to improve meaningfully in 2028, helped by launches such as entry into intracardiac echocardiography (ICE) imaging and by the Penumbra deal, which it expects to close in the second half of 2026. And if the WATCHMAN label is updated in 2027, the CEO says there could be upside to the numbers.

The real decision is size. Both ends of the band are live, and neither gets settled until the WATCHMAN market turns or a 2027 label update arrives. A position here should be one you could watch fall about 35% without being forced to sell. Compare this band with the stocks the options market expects to move most.

Can You Hold BSX Stock Through Another Year This Volatile?

A wide band is hard to sit through while management is still resetting its own forecasts. You carry every guidance cut yourself. The Trefis High Quality Portfolio spreads that risk across a set of quality businesses, so no one company’s reset decides your result. That portfolio has a track record of outpacing the three major indices.